Overview

A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation

Status:
Terminated
Trial end date:
2017-08-15
Target enrollment:
Participant gender:
Summary
This is a safety and efficacy study of OnabotulinumtoxinA for the treatment of premature ejaculation (PE) in male participants.
Phase:
Phase 2
Details
Lead Sponsor:
Allergan
Treatments:
abobotulinumtoxinA
Botulinum Toxins
Botulinum Toxins, Type A
incobotulinumtoxinA
onabotulinumtoxinA